Revenue, 2025

USD 856.07 Million

Forecast, 2035

USD 2034.08 Million

CAGR, 2026-2035

9.04%

Report Coverage

Global

Veterinary Stem Cell Therapy Market Trends for 2026

The global veterinary stem cell therapy market size was estimated at USD 856.07 million in 2025 and is predicted to increase from USD 933.46 million in 2026 to approximately USD 2034.08 million by 2035, expanding at a CAGR of 9.04% from 2026 to 2035.

The growing pet health awareness is increasing the adoption of veterinary stem cell therapies. The growing advancements in the veterinary R&D activities, rising pet ownership, and launch of new regenerative medications are also enhancing the market growth.

Key Takeaways

• The veterinary stem cell therapy market will likely exceed USD 933.46 million by 2026.
• Valuation is projected to hit USD 2034.08 million by 2035.
• Estimated to grow at a CAGR of 9.04% starting from 2026 to 2035.
• North America held the major revenue share of 40% of the global veterinary stem cell therapy market in 2025.
• Asia Pacific held the second-largest share of 15% of the market in 2025 and is expected to grow at the fastest CAGR of 9.40% during the forecast period.
• By product type, the cell-based products segment dominated the market with 55% share in 2025.
• By product type, the media & consumables segment held the second-largest share of 25% in 2025 and is expected to grow at the fastest CAGR of 10.20% during the forecast period.
• By application type, the orthopedic disorders segment held a dominant revenue share of 40% of the market in 2025.
• By application type, the neurological disorders segment held the second-largest share of 30% of the market in 2025 and is expected to grow at the highest CAGR of 10.10% during the forecast period.
• By end user, the veterinary clinics segment held a dominant position in the veterinary stem cell therapy market with a share of 60% in 2025 and is expected to grow at a notable CAGR of 8.40% during the forecast period.
• By end user, the research institutes segment held the second-largest share of 25% in 2025.

What is Veterinary Stem Cell Therapy?

The veterinary stem cell therapy market is fuelled by the growing prevalence of chronic and degenerative conditions and a shift towards pet humanization. The veterinary stem cell therapy refers to the treatment options utilizing stem cells for the treatment, regeneration, and repair of damaged organs or tissues in animals. These therapies are used for the treatment of various chronic diseases in animals, where they treat the disease by regeneration, healing, or immune modulation.

What is the Role of AI in the Market?

AI plays an important role in the veterinary stem cell therapy market as it helps in the optimization of cell culture conditions, enhancing the yield and quality of the product. It also helps in the detection of new drug molecules and targets, where it also promotes the development of personalized stem cell therapies. It also helps in identifying the success and recovery aspects associated with these therapies.

What are the Major Trends & Future Outlook of the Market?

Growing R&D Activities

The growth in R&D activities is driving the development of new veterinary stem cell therapies with enhanced safety and efficacy, where the growth in government funding is also increasing their innovations and accelerating their clinical trials.

Expanding Pet Healthcare

The growing health awareness among pet owners is fuelling the pet healthcare spending, promoting the adoption of advanced treatment options like regenerative therapies, which in turn is creating new opportunities for veterinary stem cell therapies.

Blooming Collaborations

To offer safe, effective, personalized, and affordable treatment options to the animals, new collaborations among the research institutions, veterinary clinics, and biotech firms are being formed, where their growing integration with telemedicine is also increasing the availability of veterinary stem cell therapies.

Key Indicators and Highlights

Segmental Insights

By Product Type Insights

The Cell-based Products Segment Dominated the Market in 2025

The cell-based products segment held the largest revenue share of 55% of the veterinary stem cell therapy market in 2025, due to growth in the demand for personalized medicines. The enhanced effectiveness and targeted action also increased their use. Their faster recovery and improved safety profile also promoted their acceptance rates.

The media & consumables segment held the second-largest share of 25% of the market in 2025, and is estimated to grow at a CAGR of 10.20%, driven by the repeated use in the development of every therapy. The growing advancements in the culture media development are also increasing their demand. Additionally, the growing development of new veterinary stem cell therapies is also increasing their use.

The equipment segment held 20% share of the market in 2025, due to growing R&D activities and clinical trials of the stem cell therapies. The expanding regenerative therapy centres and in-house stem cell process facilities are also increasing their use. The growing demand for advanced equipment is also increasing its adoption rates.

By Application Insights

The Orthopedic Disorders Segment Dominated the Market in 2025

The orthopedic disorders segment contributed the biggest revenue share of 40% of the veterinary stem cell therapy market in 2025, due to growth in the musculoskeletal injuries and osteoarthritis. This increased the use of stem cell therapy to promote cartilage repair and overcome joint disease. Moreover, their affordability promoted their use over the surgeries.

The neurological disorders segment held the second-largest share of 30% of the market in 2025, and is estimated to grow at the fastest rate of 10.10%, due to their growing incidence. The high unmet medical need also increased the use of veterinary stem cell therapy. Additionally, their enhanced effectiveness and growing R&D activities are also increasing their use.

The dermatological disorders segment held 15% share of the market in 2025, due to growing demand for advanced wound healing therapies. This is increasing the use of veterinary stem cell therapy for the treatment of a wide range of skin conditions. Furthermore, the growing skin diseases and advancements in stem cell therapies are also increasing their use.

The cardiac disorders segment held 10% share of the market in 2025, due to growing heart disease in animals and limited heart tissue healing solutions. Additionally, poor conventional therapy and high mortality rates are also increasing the use of veterinary stem cell therapy. The growing focus on myocardial injury repair is also driving their innovations.

The general therapeutics segment held 5% share of the market in 2025, due to growing applications of stem cell therapy in inflammatory conditions. Their ability to treat complex and chronic disease are also increasing their adoption rates. Their growing advancements and expanding use in tissue repair are also increasing their use.

By End User Insights

The Veterinary Clinics Segment Dominated the Market in 2025

The veterinary clinics segment accounted for the highest revenue share of 60% of the veterinary stem cell therapy market in 2025, and is estimated to grow at the highest CAGR of 8.40%, as they were considered the primary point-of-care options. The growth in the patient volume and availability of skilled veterinarians has also increased their preference. Increased availability of stem cell services also increased their use.

The research institutes segment held the second-largest share of 25% of the market in 2025, due to expanding stem cell R&D activities. The growing investments and funding are also accelerating the development of new veterinary stem cell therapy. The growing collaborations, technological advancements, and expanding applications are also driving their innovations.

The hospitals segment held 15% share in the market in 2025, driven by the expanding applications in the treatment of various animal diseases. The growing complex cases and high treatment volume are also increasing their use. Furthermore, the presence of expertise and specialized equipment is also attracting the pet owners.

Regional Insights

Rise in Pet Healthcare Spending Drives North America

North America dominated the veterinary stem cell therapy market with 40% in 2025, due to a growth in pet healthcare spending and pet ownership. The presence of well-developed veterinary infrastructure also increased the use of veterinary stem cell therapy.  Additionally, growth in their orthopaedic diseases and adoption of advanced technologies also increased their use and innovations, which contributed to the market growth.

U.S. Market Trends

The growing willingness of the pet owner to invest in advanced therapies like veterinary stem cell therapy in the U.S. is increasing, driving their rapid adoption. This is promoting the development of new regenerative medicines, where their growing collaborations are also accelerating these researches. Furthermore, advanced veterinary infrastructure is also enhancing the availability of these therapies.

Increasing Pet Ownership Boost Asia Pacific

Asia Pacific is seen to grow at a CAGR of 9.40% during the forecast period, and it also held a considerable share of 15% of the veterinary stem cell therapy market in 2025, due to growing pet ownership and disposable income. The expanding veterinary infrastructure and their health awareness are also increasing the adoption of veterinary stem cell therapies. Expanding R&D activities and government initiatives are also increasing their use, enhancing the market growth.

China Market Trends

The growing pet ownership in China is increasing the demand for advanced treatment options for their growing chronic and orthopedic disorders. The expanding awareness, disposable incomes, and veterinary infrastructure are also increasing the adoption of veterinary stem cell therapies. Additionally, growing R&D activities and investments are also increasing their use.

Europe Driven by Advanced Veterinary Infrastructure

Europe is expected to grow significantly in the veterinary stem cell therapy market during the forecast period, due to the presence of advanced veterinary infrastructure. The growing pet health awareness and increasing pet ownership are also increasing the adoption of veterinary stem cell therapies. The growing chronic diseases, expanding R&D activities, and increasing collaborations are also fueling their innovation, which is promoting the market growth.

Due to the large pet ownership in the UK, the pet healthcare spending is increasing, driving the adoption of veterinary stem cell therapies. The presence of advanced veterinary clinics and the launch of new veterinary stem cell therapies are also increasing their adoption rates. Growing orthopaedic diseases and growing awareness are also increasing their demand.

Market Ecosystem Analysis

Market Value Chain Analysis

R&D

• The R&D of veterinary stem cell therapy focuses on the development of allogeneic stem cell treatments and the use of iPSC technologies.
• Key players: Gallant, VetStem Biopharma, and Boehringer Ingelheim.

Clinical Trials and Regulatory Approvals

• The safety, efficacy, and manufacturing consistency are evaluated in the clinical trials and regulatory approvals of the veterinary stem cell therapy.
• Key players: Aratana Therapeutics, VetStem Biopharma, and Boehringer Ingelheim.

Packaging and Serialization

• The packaging and sterilization of the veterinary stem cell therapy involves the use of medical-grade cryogenic vials or prefilled syringes with unique 2D data matrix barcodes for traceability and cold chain integrity.
• Key players: Arti-Cell Forte, VetStem Biopharma, Boehringer Ingelheim.

Patient Support and Services

• The veterinary training certificates, long-term biobanking services, and owner educational portal are provided in the patient support and services of the veterinary stem cell therapy.
• Key players: Gallant and VetStem Biopharma.

Market Top Vendors and Their Offerings

Market Share Influence Assessment

Competitive Landscape

SWOT Analysis

Strengths

• The veterinary stem cell therapy helps in repairing and regenerating tissue damage, which increases their adoption rates.
• Their ability to target root causes also increases their use in the treatment of degenerative or other chronic diseases.
• Their minimally invasive approach and availability of personalized treatments are also increasing their use.
• Their minimal side effects and faster recovery also increase their acceptance rates.

Weaknesses

• High cost associated with the procedures and equipment acts as the major weakness in the veterinary stem cell therapy market, limiting its use.
• Variable effectiveness and the need for specialised infrastructure also reduce their adoption rates.

Opportunities

• The growing number of pet ownerships are increasing the demand for advanced treatment options, driving the use of veterinary stem cell therapies.
• The growing awareness among pet owners is also increasing their use.
• Rising incidences of chronic animal diseases are also increasing their adoption rates.
• The technological advancements and R&D activities are also propelling their innovations.

Threats

• The high cost associated with cell processing, quality control, and culture media makes the veterinary stem cell therapy expensive, limiting its accessibility.
• Complex procedure and risk of contamination also slow down or limit their innovations.

What are the Recent Developments in the Market?

• In August 2025, India's first animal stem cell biobank was inaugurated by Dr. Jitendra Singh, the Union Minister of State, where the biobank, situated at Gachibowli, will store, preserve, and provide high-quality stem cells of various animal species and affordable culture media to the veterinary clinics, hospitals, industry, and research institutes.
• In March 2026, with a pending approval by the U.S. Food and Drug Administration Center for Veterinary Medicine (FDA-CVM) for off-the-shelf veterinary stem cell therapy developed by Gallant, the company is making strides by announcing an agreement with MWI Animal Health (MWI) to develop the first-ever ultra-low temperature cold chain for veterinary medicine.

Segments Covered in the Report

By Product Type

• Cell-based Products
  • Autologous Stem Cells
  • Allogeneic Stem Cells
• Media & Consumables
• Equipment
  • Bioreactors
  • Cryopreservation Equipment

By Application

• Orthopedic Disorders
  • Bone Injuries
  • Cartilage Injuries
• Neurological Disorders
  • Spinal Cord Injuries
  • Degenerative Nerve Diseases
• Dermatological Disorders
  • Wound Healing
  • Skin Regeneration
• Cardiac Disorders
  • Myocardial Injury
• General Therapeutics
  • Inflammatory Disorders

By End User

• Veterinary Clinics
• Research Institutes
• Hospitals

By Region

• North America
  • U.S.
  • Canada
  • Mexico
  • Rest of North America
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe
  • Western Europe
    • Germany
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal
    • Belgium
    • Ireland
    • UK
    • Iceland
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe
    • Austria
    • Russia & Belarus
    • Türkiye
    • Albania
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • Taiwan
  • India
  • Japan
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea
  • Rest of APAC
• MEA
  • GCC Countries
    • Saudi Arabia
    • United Arab Emirates (UAE)
    • Qatar
    • Kuwait
    • Oman
    • Bahrain
  • South Africa
  • Egypt
  • Rest of MEA